Ulipristal

Drug Overview

Ulipristal is a highly specialized medication within the Gynecology category. It belongs to a unique drug class known as Selective Progesterone Receptor Modulators (SPRMs). As a sophisticated Hormone Modulator, this medication has transformed how we approach both emergency pregnancy prevention and the medical management of complex uterine conditions.

Depending on the prescribed dose and treatment duration, this Targeted Therapy can either halt ovulation to prevent an unplanned pregnancy or shrink non-cancerous uterine tumors, offering a less invasive alternative to surgery for many women worldwide.

• Generic Name / Active Ingredient: Ulipristal acetate
• US Brand Names: ella (for emergency contraception)
• International Brand Names: ellaOne (emergency contraception), Esmya, Fibristal (for uterine fibroids – availability varies by country)
• Route of Administration: Oral (tablet)
• FDA Approval Status: FDA-Approved for emergency contraception. (Note: The daily dose for fibroid treatment is approved in several European and international markets under strict monitoring but has not been FDA-approved in the United States due to liver safety concerns).

What Is It and How Does It Work? (Mechanism of Action)

Ulipristal is a synthetic compound that acts directly on the body’s progesterone receptors. Progesterone is a crucial hormone for ovulation, preparing the uterine lining for a fertilized egg, and sustaining early pregnancy. Progesterone is also a key growth factor for uterine fibroids. As an advanced Hormone Modulator, ulipristal binds to these receptors but does not activate them normally. Instead, it blocks or alters the effects of natural progesterone.

The mechanism depends heavily on how and when it is used:

• In Emergency Contraception (Single High Dose): Ulipristal disrupts the hypothalamic-pituitary-ovarian (HPO) axis. Even if a woman’s luteinizing hormone (LH) levels have started to rise (the signal that triggers the ovary to release an egg), ulipristal blocks the progesterone receptors in the ovary. This temporarily halts the rupture of the ovarian follicle, delaying ovulation for up to 5 days. Because sperm can only live in the female reproductive tract for up to 5 days, delaying ovulation ensures the sperm die before an egg is ever released.
• In Uterine Fibroids (Daily Low Dose): Fibroids rely on progesterone to grow. Ulipristal acts directly on the fibroid tissue. By blocking the progesterone receptors, it stops the fibroid cells from dividing (proliferation) and induces targeted cell death (apoptosis). Simultaneously, it acts directly on the uterine lining (endometrium) to rapidly stop heavy menstrual bleeding, often within the first week of treatment.

FDA-Approved Clinical Indications

Ulipristal has distinct uses depending on regional regulatory approvals and the specific dosage formulated.

• Primary Gynecological/Obstetric Indications:
  • Emergency Contraception: Prevention of pregnancy following unprotected intercourse or a known contraceptive failure. It is approved for use up to 120 hours (5 days) after the event.
• Off-Label / Endocrinological / International Indications:
  • Uterine Fibroids (Leiomyomas): Pre-operative or intermittent medical treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. (Approved primarily in European and Canadian markets; heavily restricted due to safety protocols).
  • Heavy Menstrual Bleeding (Menorrhagia): Specifically, when bleeding is associated with the presence of uterine fibroids.

Dosage and Administration Protocols

Because the drug serves two vastly different purposes, the dosing protocols are completely distinct.

Special Considerations and Adjustments:

• Hepatic (Liver) Impairment: Ulipristal is absolutely not recommended for patients with severe liver disease. For the daily fibroid treatment, it is restricted for patients with any underlying liver disorders.
• Drug Interactions: Medications that induce the CYP3A4 enzyme (such as rifampin, certain anti-seizure medications, and St. John’s Wort) significantly decrease the effectiveness of ulipristal.
• Body Weight Limitations: Unlike other emergency contraceptives (like levonorgestrel) which lose effectiveness rapidly in women with a Body Mass Index (BMI) over 25, ulipristal maintains its efficacy better in heavier women, though its effectiveness may still decline slightly in women with a BMI over 35.

Clinical Efficacy and Research Results

Extensive clinical trials continue to support the efficacy of ulipristal in both emergency and chronic gynecological care:

• Emergency Contraception Efficacy: Clinical data from 2020-2024 reaffirms that ulipristal is the most effective oral emergency contraceptive available. When taken within 120 hours of unprotected sex, the pregnancy rate drops to approximately 1.5 to 1.9 percent. Crucially, studies show it is significantly more effective than standard levonorgestrel (Plan B) when taken between 72 and 120 hours after unprotected sex, and better at delaying ovulation when the LH surge has already begun.
• Fibroid Symptom Management: In European clinical trials assessing the 5 mg daily dose, over 70 percent of women achieved complete amenorrhea (cessation of menstrual bleeding), typically within 7 to 10 days of starting treatment. MRI and pelvic ultrasound data demonstrated a 20 to 50 percent reduction in total fibroid volume after a 3-month course.

Safety Profile and Side Effects

SEVERE WARNING: DRUG-INDUCED LIVER INJURY (Applies to Daily Fibroid Dose)

International health authorities (such as the European Medicines Agency) have issued severe warnings regarding the daily 5 mg dose of ulipristal used for fibroids. Cases of severe drug-induced liver injury, including acute liver failure requiring liver transplantation, have been reported. This risk is specifically tied to chronic, daily dosing and has not been associated with the single 30 mg dose used for emergency contraception.

Common Side Effects (>10%)

• For Emergency Contraception: Headache, nausea, abdominal pain, and dysmenorrhea (painful menstruation during the next period). The next menstrual cycle may arrive a few days earlier or later than expected.
• For Fibroids: Hot flashes, headaches, fatigue, and benign, reversible changes to the uterine lining (known as PAEC – Progesterone Receptor Modulator Associated Endometrial Changes).

Serious Adverse Events

• Severe hepatic failure (chronic daily use only).
• Ectopic pregnancy (if the emergency contraceptive fails and pregnancy occurs, the risk of the pregnancy being outside the uterus must be evaluated by a doctor).

Management Strategies

• Liver Monitoring: For women taking the daily fibroid dose internationally, strict liver function tests (AST/ALT blood tests) must be performed before starting treatment, monthly during treatment, and weeks after stopping. If liver enzymes become elevated, the medication must be stopped immediately.
• Nausea Management: If a patient vomits within 3 hours of taking the 30 mg emergency contraceptive tablet, a replacement dose must be prescribed and taken immediately.

Research Areas

Because systemic (oral) administration of this Hormone Modulator for chronic conditions like fibroids carries significant liver toxicity risks, modern reproductive research is heavily focused on localized, targeted drug delivery. Scientists are currently developing and testing intrauterine devices (IUDs) and vaginal rings infused with ulipristal. The goal is to deliver the medication directly to the uterine tissue to shrink fibroids and stop heavy bleeding without the drug ever having to pass through the liver in high concentrations. This targeted approach could potentially resurrect ulipristal as a primary, safe, non-surgical treatment for millions of women suffering from severe uterine fibroids.

Disclaimer: These studies regarding the development and clinical testing of ulipristal-acetate-infused intrauterine devices (IUDs) and vaginal rings for the treatment of uterine fibroids are currently in the preclinical or early clinical phase and are not yet applicable to practical or professional clinical scenarios

Patient Management and Practical Recommendations

Pre-treatment Tests

• Pregnancy Test: Mandatory before starting the daily fibroid treatment. Highly recommended before taking the emergency contraceptive to ensure the patient is not already pregnant from a previous encounter.
• Liver Function Panel (AST, ALT, Bilirubin): Strictly required before, during, and after chronic treatment for uterine fibroids.

Precautions During Treatment

• Breastfeeding: Ulipristal passes into breast milk. It is recommended to pump and discard breast milk for 7 days after taking the emergency contraceptive dose.
• Restarting Birth Control: Because ulipristal blocks progesterone, it can counteract your regular hormonal birth control pills. After taking emergency contraception, you must wait 5 days before resuming your regular daily birth control pill, patch, or ring. You must use barrier methods (like condoms) during those 5 days and until your next menstrual period.

Do’s and Don’ts

• DO take the emergency contraceptive dose as quickly as possible; time is of the essence.
• DO use condoms if you have sex again in the same menstrual cycle, as the single pill only protects against past unprotected encounters, not future ones.
• DO contact your doctor immediately if you experience severe lower abdominal pain weeks after taking the emergency pill, to rule out an ectopic pregnancy.
• DON’T use ulipristal as a regular, routine method of birth control.
• DON’T take standard daily birth control pills on the same day you take ulipristal for emergency contraception.
• DON’T ignore signs of liver trouble (such as yellowing of the eyes/skin, dark urine, or upper right stomach pain) if you are on the daily fibroid treatment regimen.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, gynecologist, or other qualified healthcare provider with any questions you may have regarding a medical condition, medication, or emergency contraceptive needs. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.